SARS-CoV-2

Paul-Albert Koenig1,2, Hrishikesh Das3, Hejun Liu4

  • 1Core Facility Nanobodies, Medical Faculty, University of Bonn, 53127 Bonn, Germany. pakoenig@uni-bonn.de martin.hallberg@ki.se nicwu@illinois.edu fschmidt@uni-bonn.de.

Science (New York, N.Y.)
|January 13, 2021
PubMed
概括

研究人员开发了针对SARS-CoV-2尖端蛋白的强大纳米体,用于被动免疫. 这些工程纳米体表现出卓越的中和活性,并阻止了耐药病毒菌株的出现.